安罗替尼联合替吉奥在晚期肺鳞癌三线治疗中的临床研究

Clinical study of combination of Anlotinib and Tegafur in the third line treatment of advanced lung squamous cell carcinoma

目的探讨安罗替尼联合替吉奥在晚期肺鳞癌三线治疗中的临床价值。方法选取江西省萍乡市萍矿总医院2018年9月~2019年9月诊断为肺鳞癌Ⅳ期,且经过二线治疗进展的60例患者,按照随机数字表法分为治疗组、对照1组与对照2组,每组各20例。其中治疗组采取安罗替尼+替吉奥治疗,对照1组采取安罗替尼+安慰剂治疗,对照2组采取替吉奥+安慰剂治疗。比较三组的治疗效果与不良反应发生情况。结果三组无进展生存期(PFS)比较,治疗组明显长于对照1组及2组,差异有统计学意义(P<0.05);三组客观缓解率(ORR)比较,差异无统计学意义(P>0.05);三组疾病控制率(DCR)比较,治疗组高于对照1组与对照2组,且总生存期(OS)长于对照1组与对照2组,差异有统计学意义(P<0.05);三组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论安罗替尼联合替吉奥可有效控制患者病情发展,延长患者生存时间,且未增加严重不良反应,值得推广。

Objective To investigate the clinical value of Anlotinib combined with S-1 in the treatment of advanced lung squamous cell carcinoma.Methods A total of 60 patients who were diagnosed with lung squamous cell carcinoma stageⅣand had progressed through second-line treatment were selected in Pingkuang General Hospital,Pingxiang City,Jiangxi Province from September 2018 to September 2019.They were divided into treatment group,control group 1 and control group 2 according to the random number table method,20 cases in each group.The treatment group was treated with Anlotinib+Tiggio,the control group 1 was treated with Anlotinib+placebo,and the control group 2 was treated with Tiggio+placebo.The treatment effect and adverse reactions of the three groups were compared.Results The progression free survival(PFS)of the treatment group was longer than that of the control group 1 and 2,the difference was statistically significant(P<0.05);comparison the objective remission rate(ORR)of the three groups,the difference was not statistically significant(P>0.05).The disease control rate(DCR)of the treatment group was higher than that of the control group 1 and 2,and the overall survival time(OS)was longer than that of the control group 1 and 2,there were significant differences(P<0.05).There was no significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion The combination of Anlotinib and Tegafur treatment can effectively control the development of patients′condition,prolong the survival time of patients,and does not increase serious adverse reactions,which is worthy of promotion.